Neutralizing and Binding Antibodies to IFN-β: Relative Frequency in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different IFN-βPreparations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

1996 • 361 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice.

1997 • 294 citations

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1998 • 292 citations

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1988 • 251 citations

Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

2000 • 223 citations

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

1990 • 207 citations

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1999 • 194 citations

Site-specific mutagenesis of the human fibroblast interferon gene.

1984 • 193 citations

Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis

2003 • 183 citations

Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia

1991 • 148 citations

[74] Quantitation of neutralization of interferon by antibody

1986 • 127 citations

Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection

1987 • 121 citations

Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up

1993 • 109 citations

Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.

1989 • 101 citations

Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

2000 • 96 citations

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy

1996 • 85 citations

Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection

1993 • 84 citations

Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection

1990 • 81 citations

Neutralizing and binding anti‐interferon‐β (IFN‐β) antibodies. A comparison between IFN‐β‐1a and IFN‐β‐1b treatment in multiple sclerosis

2000 • 77 citations

Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a

1998 • 75 citations

Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive

1998 • 74 citations

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1999 • 63 citations

Effective natural interferon-alpha therapy in recombinant interferon- alpha-resistant patients with hairy cell leukemia

1991 • 63 citations

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

2003 • 62 citations

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN–α) during therapy for chronic hepatitis C

1994 • 60 citations

Effective natural interferon-alpha therapy in recombinant interferon- alpha-resistant patients with hairy cell leukemia

1991 • 58 citations

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2α

1994 • 55 citations

Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.

1997 • 53 citations

Development of antibodies to interferon beta in patients: technical and biological aspects.

1999 • 51 citations

Management of multiple sclerosis: current trials and future options

2003 • 36 citations

In vivo development of antibody to interferons: an update to 1996.

1997 • 32 citations

Characterization of four different mammalian‐cell‐derived recombinant human interferon‐β1s

1989 • 32 citations

The expression of potency of neutralizing antibodies for interferons and other cytokines

1997 • 31 citations

Neutralising and binding anti-interferon-β-1 b (IFN-b-1 b) antibodies during IFN-β-1 b treatment of multiple sclerosis

1997 • 31 citations

Neutralizing antibodies in gene-defective hosts

2003 • 17 citations

Introduction

1989 • 14 citations

Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection

2002 • 10 citations

Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis

2003 • 5 citations

Pharmacokinetics of recombinant interferon (IFN)-α in a hepatitis patient with neutralizing antibody to IFN

1997 • 3 citations

Book Review

1998 • 1 citations